CO2023004963A2 - Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden - Google Patents
Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprendenInfo
- Publication number
- CO2023004963A2 CO2023004963A2 CONC2023/0004963A CO2023004963A CO2023004963A2 CO 2023004963 A2 CO2023004963 A2 CO 2023004963A2 CO 2023004963 A CO2023004963 A CO 2023004963A CO 2023004963 A2 CO2023004963 A2 CO 2023004963A2
- Authority
- CO
- Colombia
- Prior art keywords
- chimeric protein
- protein
- receptor
- binding domain
- compositions
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 3
- 101710132601 Capsid protein Proteins 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención provee una proteína quimérica que posee una estructura modular y que comprende un dominio de unión al receptor (RBD) de la proteína de la espiga (S) de coronavirus, un segmento con capacidad de unión al antígeno de la nucleocápsida del virus de la hepatitis B (HBcAg), un segmento que comprende la secuencia de aminoácidos HHHHHH, y dos segmentos espaciadores. En la proteína quimérica los segmentos se disponen en un orden específico, y esta tiene la capacidad de formar nanopartículas híbridas con el HBcAg. La proteína quimérica forma parte de composiciones vacunales para la prevención de las infecciones causadas por coronavirus. Por tanto, la invención revela un método de prevención de una infección causada por coronavirus donde se administra una composición vacunal que comprende dicha proteína quimérica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
| PCT/CU2021/050010 WO2022096039A1 (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023004963A2 true CO2023004963A2 (es) | 2023-06-20 |
Family
ID=79164940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0004963A CO2023004963A2 (es) | 2020-11-04 | 2023-04-20 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405106A1 (es) |
| EP (1) | EP4242222A1 (es) |
| JP (1) | JP2023548205A (es) |
| CN (1) | CN116802194A (es) |
| AR (1) | AR123998A1 (es) |
| AU (1) | AU2021373188A1 (es) |
| CA (1) | CA3197024A1 (es) |
| CO (1) | CO2023004963A2 (es) |
| CU (1) | CU24665B1 (es) |
| MX (1) | MX2023005211A (es) |
| WO (1) | WO2022096039A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| CN111620952A (zh) * | 2020-06-17 | 2020-09-04 | 苏州米迪生物技术有限公司 | 基于嵌合型病毒样颗粒的新型冠状病毒疫苗 |
| CN111676248A (zh) * | 2020-07-02 | 2020-09-18 | 军事科学院军事医学研究院军事兽医研究所 | 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建 |
-
2020
- 2020-11-04 CU CU2020000081A patent/CU24665B1/es unknown
-
2021
- 2021-11-03 CN CN202180088951.7A patent/CN116802194A/zh active Pending
- 2021-11-03 MX MX2023005211A patent/MX2023005211A/es unknown
- 2021-11-03 US US18/035,254 patent/US20230405106A1/en active Pending
- 2021-11-03 JP JP2023527114A patent/JP2023548205A/ja active Pending
- 2021-11-03 WO PCT/CU2021/050010 patent/WO2022096039A1/es active Application Filing
- 2021-11-03 CA CA3197024A patent/CA3197024A1/en active Pending
- 2021-11-03 EP EP21834711.0A patent/EP4242222A1/en active Pending
- 2021-11-03 AU AU2021373188A patent/AU2021373188A1/en active Pending
- 2021-11-04 AR ARP210103065A patent/AR123998A1/es unknown
-
2023
- 2023-04-20 CO CONC2023/0004963A patent/CO2023004963A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3197024A1 (en) | 2022-05-12 |
| WO2022096039A1 (es) | 2022-05-12 |
| CU24665B1 (es) | 2023-06-13 |
| CN116802194A (zh) | 2023-09-22 |
| AR123998A1 (es) | 2023-02-01 |
| CU20200081A7 (es) | 2022-06-06 |
| MX2023005211A (es) | 2023-05-16 |
| AU2021373188A1 (en) | 2023-06-01 |
| US20230405106A1 (en) | 2023-12-21 |
| JP2023548205A (ja) | 2023-11-15 |
| EP4242222A1 (en) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022015415A2 (es) | Aplicación antiviral de análogo de nucleósido o formulación combinada que contiene análogo de nucleósido | |
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| CY1122291T1 (el) | Αναστολeις ιικου αναδιπλασιασμου | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| BR112018067964A2 (pt) | agentes antivirais para hepatite b | |
| CO6390077A2 (es) | Inhibidores de hacv ns5a | |
| CR8935A (es) | Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones | |
| BR112018009009A8 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
| CL2008002995A1 (es) | Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih. | |
| UY35362A (es) | Compuestos terapéuticos | |
| EA201791776A1 (ru) | Замещенные циклофаны для использования при лечении инфекции вгс | |
| BR112015013695A2 (pt) | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv | |
| DOP2022000293A (es) | Análogos de nucleósido de 1-ciano y usos de los mismos | |
| GB2503066A8 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| ECSP22026797A (es) | Composiciones y métodos para el tratamiento de infecciones virales | |
| AR088580A1 (es) | Metodos y composiciones para tratar el virus de la hepatitis c | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| CO2022008701A2 (es) | Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter | |
| BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids | |
| BR112023000220A2 (pt) | Formulações de longa ação | |
| MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
| EA201300805A1 (ru) | Производные фенилизоксазола и способ его получения | |
| CO2022014992A2 (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica |